Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C35H42N2O9 |
Molecular Weight | 634.716 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 1 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@]12C[C@@H](OC(=O)\C=C\C3=CC(OC)=C(OC)C(OC)=C3)[C@H](OC)[C@@H](C(=O)OC)[C@@]1([H])C[C@@]4([H])N(CCC5=C4NC6=C5C=CC(OC)=C6)C2
InChI
InChIKey=SZLZWPPUNLXJEA-QEGASFHISA-N
InChI=1S/C35H42N2O9/c1-40-21-8-9-22-23-11-12-37-18-20-15-29(46-30(38)10-7-19-13-27(41-2)33(43-4)28(14-19)42-3)34(44-5)31(35(39)45-6)24(20)17-26(37)32(23)36-25(22)16-21/h7-10,13-14,16,20,24,26,29,31,34,36H,11-12,15,17-18H2,1-6H3/b10-7+/t20-,24+,26-,29-,31+,34+/m1/s1
Originator
Approval Year
Doses
Dose | Population | Adverse events |
---|---|---|
15 mg single, parenteral Highest studied dose Dose: 15 mg Route: parenteral Route: single Dose: 15 mg Sources: |
unhealthy n = 3 Health Status: unhealthy Condition: hypertension Population Size: 3 Sources: |
Other AEs: Weakness, Dizziness... |
4 mg 1 times / day multiple, oral Highest studied dose Dose: 4 mg, 1 times / day Route: oral Route: multiple Dose: 4 mg, 1 times / day Sources: |
unhealthy n = 10 Health Status: unhealthy Condition: hypertension Population Size: 10 Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Dizziness | 15 mg single, parenteral Highest studied dose Dose: 15 mg Route: parenteral Route: single Dose: 15 mg Sources: |
unhealthy n = 3 Health Status: unhealthy Condition: hypertension Population Size: 3 Sources: |
|
Nasal congestion | 15 mg single, parenteral Highest studied dose Dose: 15 mg Route: parenteral Route: single Dose: 15 mg Sources: |
unhealthy n = 3 Health Status: unhealthy Condition: hypertension Population Size: 3 Sources: |
|
Weakness | 15 mg single, parenteral Highest studied dose Dose: 15 mg Route: parenteral Route: single Dose: 15 mg Sources: |
unhealthy n = 3 Health Status: unhealthy Condition: hypertension Population Size: 3 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [IC50 1.53 uM] | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/31828069/ |
yes | |||
yes | ||||
Sources: https://pubmed.ncbi.nlm.nih.gov/7476894/ |
yes |
PubMed
Title | Date | PubMed |
---|---|---|
A structure-function relationship among reserpine and yohimbine analogues in their ability to increase expression of mdr1 and P-glycoprotein in a human colon carcinoma cell line. | 1995 Oct |
|
Small molecules targeting severe acute respiratory syndrome human coronavirus. | 2004 Jul 6 |
|
Search of chemical scaffolds for novel antituberculosis agents. | 2005 Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/13284667
From 1 to 2 mg of rescinnamine are given orally.
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C270
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
||
|
WHO-VATC |
QC02LA02
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
||
|
WHO-VATC |
QC02LA52
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
||
|
WHO-ATC |
C02AA01
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
||
|
WHO-VATC |
QC02AA01
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
||
|
WHO-ATC |
C02LA52
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
||
|
WHO-ATC |
C02LA02
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1668
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
DB01180
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
SUB10285MIG
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
28572
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
24815-24-5
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
15628
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
Q6W1F7DJ2D
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
5280954
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
m9532
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | Merck Index | ||
|
2369
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
7098
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
DTXSID3023554
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
683
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
100000080551
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
Rescinnamine
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
C61923
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
9259
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | RxNorm | ||
|
2176
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY | |||
|
246-471-8
Created by
admin on Fri Dec 15 16:03:29 GMT 2023 , Edited by admin on Fri Dec 15 16:03:29 GMT 2023
|
PRIMARY |
ACTIVE MOIETY